In this conversation, David Moss, CEO of INmune Bio, discusses his journey in the biotech industry, the founding of INmune Bio, and the company's focus on modulating the innate immune system to develop therapies for diseases like Alzheimer's and rare pediatric conditions. He emphasizes the importance of scientific integrity in research and the challenges faced in the Alzheimer's space, while also sharing his personal motivations for driving the company's mission forward.TakeawaysDavid Moss has a long-standing passion for biotech, influenced by family connections.INmune Bio focuses on the innate immune system, which is often overlooked in drug development.The company was founded to create affordable therapies for complex diseases.Their product platforms include Chordstrom for rare diseases and Expro for Alzheimer's.Alzheimer's disease represents a significant unmet medical need with millions affected.Recruiting patients for clinical trials is a structured process, not a marketing campaign.David's personal connection to Alzheimer's motivates his work at INmune Bio.The company aims to disrupt chronic inflammation to improve cognitive function.Expro is designed to be a lifelong treatment for Alzheimer's patients.INmune Bio is open to discussions with investors and interested parties.INmune Bio website: https://www.inmunebio.com/Nano Cap Podcast Website: https://www.nanocappod.com/DISCLAIMER - The contents of this podcast are for informational purposes only and do not constitute financial, investment, legal, or other professional advice. Listeners should not construe any information discussed as a recommendation to buy, sell, or hold any securities or investments. Always consult with a qualified financial advisor or professional before making any financial decisions.

Ver todos los episodios